Preprint Concept Paper Version 1 Preserved in Portico This version is not peer-reviewed

Mirage or Miracle—Intraovarian Autologous Platelet Cytokines for Infertility and Menopause

Version 1 : Received: 8 June 2022 / Approved: 9 June 2022 / Online: 9 June 2022 (11:16:03 CEST)

A peer-reviewed article of this Preprint also exists.

Sills ES, Wood SH, Walsh APH. Intraovarian condensed platelet cytokines for infertility and menopause—Mirage or miracle? Biochimie 2022; in press. Sills ES, Wood SH, Walsh APH. Intraovarian condensed platelet cytokines for infertility and menopause—Mirage or miracle? Biochimie 2022; in press.

Abstract

On a bleak therapeutic landscape unchanged since the 1980’s, IVF with egg donation still stand as the lone medical answer to diminished reserve and premature ovarian insufficiency. Intraovarian platelet-rich plasma (PRP) crossed the horizon in 2016 as hopeful answer to these intertwined problems. The once remote mirage of platelet cytokine effects on gene regulation or telomere stabilization is now in sharper focus, and current work is clarifying how PRP corrects oxidative stress, rectifies tissue hypoxia, downregulates apoptosis, and enhances cellular metabolism. Not yet ready for routine use, this investigational treatment does offer one point of general agreement: How intraovarian PRP results should be classified—Patients are either responders or non-responders. From this, it is intriguing that no published PRP protocol has reported a supranormal ovarian rebound or hyperstimulation effect. This could be explained by baseline age-related ovarian conditions prevalent among poor responders, but since dysregulated or malignant transformations are also absent in other tissue contexts following autologous PRP treatment, the contribution of some platelet product which intrinsically delimits regenerative action cannot be discounted. Here we summarize results with recent experimental and clinical platelet research, framing those most likely to help advance reproductive endocrinology practice.

Keywords

ovary; PRP; senescence; rejuvenation; hypoxia; telomere length

Subject

Medicine and Pharmacology, Obstetrics and Gynaecology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.